Innate Pharma participates in the 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference on March 26, 2024, discussing immunotherapy for cancer.
Innate Pharma, a global clinical-stage biotech firm, will participate in the 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference on March 26, 2024. Executive team members will share updates on their work in immunotherapy for cancer using the innate immune system and ANKET® technology. Their lead programs include lacutamab for CTCL and PCTL, along with monalizumab, developed with AstraZeneca for NSCLC.
March 19, 2024
4 Articles